Skip to main content
Meagan Jacoby, MD, Oncology, Saint Louis, MO

Meagan Anne Jacoby MD

Hematologic Oncology


Instructor, Internal Medicine, Washington University School of Medicine

Join to View Full Profile
  • 4921 Parkview Pl# DvSaint Louis, MO 63110

  • Phone+1 314-454-8304

  • Fax+1 314-454-5902

Dr. Jacoby is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2011
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2005 - 2007
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 2005

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 2011 - 2026
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Exome Analysis of Treatment‐Related AML After APL Suggests Secondary Evolution  
    John S Welch, Eric J Duncavage, Meagan A Jacoby, Peter Westervelt, Lukas D Wartman, British Journal of Haematology
  • Virescent Tongue  
    Rizwan Romee, Meagan Jacoby, Annals of Hematology

Abstracts/Posters

  • A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Na¥ve Patients with Higher-Risk Myelodysplastic Syndrome
    Meagan Jacoby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
    Meagan Jacoby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • OncLive® to Host State of the Science Summit™ on Treatment of Hematologic Malignancies
    OncLive® to Host State of the Science Summit™ on Treatment of Hematologic MalignanciesNovember 5th, 2018
  • Post-Transplant Gene Mutations Predict Risk for MDS Progression
    Post-Transplant Gene Mutations Predict Risk for MDS ProgressionNovember 1st, 2018
  • Genetic Testing Helps Predict Disease Recurrence in Myelodysplastic Syndrome
    Genetic Testing Helps Predict Disease Recurrence in Myelodysplastic SyndromeSeptember 25th, 2018
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: